We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA-EMA Scientific Advice Program Continued in the Pandemic, But Overall Uptake is Low
FDA-EMA Scientific Advice Program Continued in the Pandemic, But Overall Uptake is Low
Scientists working in the FDA’s and European Medicines Agency (EMA)’s parallel scientific advice (PSA) program kept the numbers of accepted requests from sponsors level despite needing to shift many resources to address COVID-19 related public health needs, according to a new review of the program’s productivity over the last five years.